Evidence map›Paper›PMID 33552000›Full record

ReviewFrontiers in endocrinology2020

Natural Compounds in Sex Hormone-Dependent Cancers: The Role of Triterpenes as Therapeutic Agents.

Codruţa Şoica, Mirela Voicu, Roxana Ghiulai, Cristina Dehelean, Roxana Racoviceanu, Cristina Trandafirescu, Oana-Janina Roșca, Gabriela Nistor, Marius Mioc, Alexandra Mioc

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Preventive Effects ofInternational journal of molecular sciences · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. AnIranian journal of basic medical sciences · 2023
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Codruţa ŞoicaFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Mirela VoicuFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Roxana GhiulaiFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Cristina DeheleanFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Roxana RacoviceanuFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Cristina TrandafirescuFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Oana-Janina RoșcaFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Gabriela NistorFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Marius MiocFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Alexandra MiocFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Victor Babeș University of Medicine and Pharmacy Timișoara · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sex hormone-dependent cancers currently contribute to the high number of cancer-related deaths worldwide. The study and elucidation of the molecular mechanisms underlying the progression of these tumors was a double-edged sword, leading to the expansion and development of new treatment options, with the cost of triggering more aggressive, therapy resistant relapses. The interaction of androgen, estrogen and progesterone hormones with specific receptors (AR, ER, PR) has emerged as a key player in the development and progression of breast, ovarian, prostate and endometrium cancers. Sex hormone-dependent cancers share a common and rather unique carcinogenesis mechanism involving the active role of endogenous and exogenous sex hormones to maintain high mitotic rates and increased cell proliferation thus increasing the probability of aberrant gene occurrence and accumulation highly correlated with abnormal cell division and the occurrence of malignant phenotypes. Cancer related hormone therapy has evolved, currently being associated with the blockade of other signaling pathways often associated with carcinogenesis and tumor progression in cancers, with promising results. However, despite the established developments, there are still several shortcomings to be addressed. Triterpenes are natural occurring secondary metabolites biosynthesized by various pathways starting from squalene cyclization. Due to their versatile therapeutic potential, including the extensively researched antiproliferative effect, these compounds are most definitely a cornerstone in the research and development of new natural/semisynthetic anticancer therapies. The present work thoroughly describes the ongoing research related to the antitumor activity of triterpenes in sex hormone-dependent cancers. Also, the current review highlights both the biological activity of various triterpenoid compounds and their featured mechanisms of action correlated with important chemical structural features.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicBiological ProductsFemaleGonadal Steroid HormonesHumansMaleNeoplasmsTriterpenesAntineoplastic Agents, PhytogenicBiological ProductsGonadal Steroid HormonesTriterpenesantiproliferative activityhormone-dependent cancersphytocompoundstherapeutic agentstriterpenes

Identifiers

PMID33552000
PMCPMC7859451
OpenAlexW3124380661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.